For Wednesday, April 13th
AGEL, SYMD, MTPR, LGBS, ELTP, KBLB
Our Stocks to Watch tomorrow include Angel Acquisition Corp. (OTC: AGEL), SyntheMed Inc. (OTCBB: SYMD), MetaPower International Inc. (OTC: MTPR), Legends Business Group (OTC: LGBS), Elite Pharmaceuticals Inc. (OTCBB: ELTP) and Kraig Biocraft Laboratories Inc. (OTC: KBLB).
ANGEL ACQUISITION CORPORATION (OTCBB: AGEL)
"Up 100.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/AGEL.php
Angel Acquisitions Corp is a diversified asset management company that acquires and/or develops profitable companies. Angel Acquisition Corp either obtains a majority of stock in each company they gain control of or, the company internally develops profitable enterprises. Through the acquisition and development of profitable companies and the expansion of internal divisions, Angel Acquisitions Corp has the ability to experience growth through diverse holdings. Companies turning large profits are analyzed and considered for acquisition.
March 23 - Angels in Action Announces GATE Technologies Acquires Controlling Interest
GATE Global Impact Extends Its Offerings Into Microfinance
GATE Technologies, LLC, announced that it has acquired controlling interest in Angels in Action ("AIA"), an operating division of Angel Acquisition Corp. (OTC: AGEL), enhancing the offerings of its subsidiary, GATE Global Impact ("GGI"). Angels in Action is a Carlsbad, California based company focused on providing microfinance services in the U.S. marketplace. AIA's platform enables eligible American entrepreneurs to secure quick-and-ready financing through peer-to-peer loans and microloans. The terms and conditions of the sale will be announced and fully disclosed in the near term.
This acquisition enables Steve Bonenberger, CEO and Founder of AIA, to extend the mission and reach of his Microfinance Platform by increasing its exposure to leading Impact Investors. "American entrepreneurs in need of financing have come to us with their dreams when they have nowhere else to turn. Traditional banking and lending platforms have shut out entire sectors of the population due to the economic downturn. The GATE Global Impact strategic partnership and teaming involvement now enables us to deploy our vision for a new era of financing in America."
Angels in Action brings together entrepreneurs and investors in the underserved markets in the United States. AIA provides an opportunity to help America fill the financial void that has not been adequately addressed by the U.S. banking system. Mr. Bonenberger states, "There is a strong desire for Americans to assist entrepreneurs in creating their American dream. AIA will play its part in helping rebuild the financial infrastructure needed to restore the U.S. economy." Micro lending platforms have achieved incredible success in the international marketplace, and AGEL.PK and GGI collectively believe that Americans will embrace this platform domestically.
Angels in Action will serve as the microfinance stage for GATE Impact US. The GATEway platform will ultimately facilitate Impact Investing and Microfinance in the US market. This acquisition will enable GGI to achieve a more holistic solution for sustainable investments across multiple customer segments. The convergence of Community Reinvestment, Community Banking and Microfinance will create "Impact Banking" in the US. There is clearly a new customer demographic in the marketplace. Purchasing methods and tools have evolved. Microloans repaid with micro-payments. Virtual Good created with Virtual Currency. "We are proud to extend our platform in the emerging U.S. Microfinance sector, and connect with a historically overlooked demographic that has proven profitable globally," said William Davis, President of GATE Impact, LLC.
About GATE Technologies LLC
GATE Technologies is an innovative financial technology company creating new market infrastructure for bringing efficiency and transparency to the unstructured global alternative asset markets. The company offers fully automated, customizable solutions for qualified investors with value-added content and analytics, transparent execution, and dematerialized settlement, clearing, and depository functions.
About GATE Global Impact, LLC
GATE Global Impact, LLC is the impact investing-focused subsidiary of GATE Technologies, LLC. Launched in 2011, GATE Impact provides market infrastructure and related services for the emerging impact investment and banking industries — public and private investments with a sustainable social and/or environmental component that also generate a healthy rate of financial return.
SYNTHEMED INCORPORATED (OTCBB: SYMD)
"Up 100.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/SYMD.php
SyntheMed, Inc., a biomaterials company, engages in the development and commercialization of medical devices for therapeutic applications. It offers surgical implants designed to prevent or reduce the formation of adhesions/scar tissue following a range of surgical procedures. The company's lead product includes REPEL-CV, a bioresorbable film designed to be placed over the surface of the heart at the conclusion of surgery to reduce the formation of post-operative adhesions. SyntheMed offers products based on the proprietary, bioresorbable polymer technology. Its products also include REPEL-AFIB, which reduces the patient risk associated with atrial fibrillation; RESOLVE that prevents or reduces post-operative surgical adhesions in gynecological and general abdominal surgery; and RELIEVE for preventing or reducing post-operative surgical adhesions in orthopedic and spinal surgery. The company, formerly known as Life Medical Sciences, Inc., was founded in 1990 and is headquartered in Iselin, New Jersey.
March 29 - Pathfinder Cells Demonstrate Ability to Regenerate Damaged Tissue and Restore Pancreatic Function in a Diabetic Mouse Model
Positive Preclinical Data Published in Rejuvenation Research
Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage ("Pathfinder"), today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model. The results of the study, which will be printed in the April issue of Rejuvenation Research and available currently online, are the first to describe the Company's proprietary Pathfinder Cells ("PCs"), which stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue.
"Though preliminary, the robustness of these results is very encouraging," stated Paul G. Shiels, Ph.D., University of Glasgow, Glasgow, United Kingdom. "With only two treatments with PCs, just days after induction of diabetes, we were able to quickly regenerate critically damaged pancreatic tissue, restoring and maintaining normal glucose levels and healthy body weight. Importantly, these results enhance our understanding of the mechanisms of self-repair elicited by PCs, which may represent a novel cell therapy-based approach to treating diseases marked by tissue damage and loss of organ function."
Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder said, "We are pleased to share our preliminary findings for this exciting new cell-based technology. We will continue to focus our efforts on elucidating the mechanism by which PCs stimulate tissue regeneration, as well as explore the potential use of such therapy in treating diseases with high unmet need such as diabetes, cardiac ischemia, and renal reperfusion injury."
The efficacy of PC treatment was examined using the common streptozotocin (STZ)-induced diabetic mouse model. At three and ten days following administration of STZ, which destroys insulin-producing beta-cells, 1.5 million human or rat pancreas-derived PCs were injected into mice intravenously. As early as day nine, animals treated with rat or human PCs had significantly lower blood glucose than control animals (p<0.01). Animals in the control group became profoundly diabetic within one week following STZ administration, while PC-treated mice showed a progressive reduction in blood glucose, achieving normal levels by day 39 and maintaining these levels with no further treatment through day 89, at which point the study was terminated. Concurrent with the restoration of normal glucose levels, PC-treated animals recovered from an initial loss of body mass and maintained normal body weight for the remainder of the study.
Immunohistochemical analyses of animal tissues confirmed that PC treatment lead to regeneration of pancreatic beta-cells and formation of functional islets, which displayed normal architecture. Further examination determined that the regenerated islets consisted overwhelmingly of mouse cells, and to a much lesser extent, donor PCs (0.05-0.18%). The few PCs present in the islet tissue were diffused throughout sections, indicating that the PCs themselves do not form islet-like structures in vivo. Importantly, this strongly suggests that PCs activate mechanism(s) in the host that drive pancreatic islet regeneration, but which are not capable of initiating such repair in the absence of PCs.
Dr. Franklin concluded, "These data indicate the feasibility of using PCs to stimulate the regeneration of critically damaged adult tissue. The further development of PCs as a vehicle for regenerative medicine offers exciting prospects for future therapies."
Pathfinder is developing a novel cell-based therapy with the potential to revolutionize the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Leveraging its internal discovery of Pathfinder Cells ("PCs") and a proprietary means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood.
Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be "immune privileged," and their effects appear to be independent of the tissue source of PCs. In addition to diabetes, positive results have been observed in animal models of cardiac ischemia and renal reperfusion injury.
In December 2010, Pathfinder and SyntheMed, Inc. (OTCBB: SYMD) announced that the companies had entered into a definitive merger agreement. Upon closing, SyntheMed will be renamed "Pathfinder Cell Therapy, Inc." and the combined company will operate under the leadership of the Pathfinder management team, with the support of a group of regenerative medicine thought leaders on the board of directors. Closing of the merger is subject to a number of conditions.
META POWER INTERNATIONAL INCORPORATED (OTC: MTPR)
"Up 34.78% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/MTPR.php
MetaPower International, Inc. is a technology firm founded in 1996 that provides information technology and change management services to hazardous process industries. This link between technology and services is critical to enable the changes necessary to successfully compete in the current environment. In today's competitive world, business operations must be streamlined if new levels of performance and operational excellence are to be achieved.
April 12 - MetaPower International, Inc. Increases 2010 Revenue by 39 Percent as Compared to 2009 as Stated on OTCmarkets.com
MetaPower International, Inc. (OTC: MTPR) announced that the Company has posted its unaudited 2010 Year End financial report on Otcmarkets.com. MetaPower International's revenues for the year ending December 31, 2010 were $11,875,484, exceeding our target of $10.8 million for 2010 and surpassing 2009 revenues by 39%. The Company's EBITDA for 2010 was $362,580, which was all generated from operations.
In 2010 the audit of the 2007, 2008 and 2009 financial statements were completed. The audit of the 2010 Q1-Q3 were also completed by the independent auditors. Our complete 2010 financial audit will be completed by the end of Q2 2011.
The Presidents message accompanying the report outlines MetaPower's year-end results, as well as the company goals for 2011.
"We are pleased to report that 2010 was another successful year. In the four years that we have been reporting as a public company we have grown our revenues each year. We expect 2011 to continue this pattern of growth and development as a company. We have established revenue goals for 2011 of $12.5 million with an expected EBITDA of $650K. We look forward to seeing positive impacts from our new marketing campaign in 2011. Please stop by our web site to see all of the changes that are happening at MetaPower," said Ken Allen, president of MetaPower International, Inc.
LEGENDS BUSINESS GROUP INCORPORATED (OTC: LGBS)
"Up 55.56% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/LGBS.php
Legends Business Group, Inc., was incorporated in March 2006, and is a publicly traded company. The company has recently refocused its purpose and has moved itself into the alternative and exotic energy marketplace.
April 12 - Legends Business Group Adds Solar Charger Controllers to Its Web Product Line
Ten to 80 Watt Tesla Solar Trackers Now Available at www.legendspower.com
Legends Business Group (OTC: LGBS) announced it will offer a range of Tesla Solar Trackers (Solar Charger Controllers) from 10 watts to 80 watt systems.
Solar charge controllers are used to regulate the power going from the solar panels to the batteries. According to Legends President, Rolando Sablon, overcharging batteries will, at the least, significantly reduce battery life and, at worst, damage the batteries to the point that they are unusable. He said that solar charge controllers are a necessity in practically all solar power systems that utilize batteries.
"If you are thinking about using solar panels to charge one or more batteries, there is one piece of equipment that will significantly increase your energy harvest — a solar charge controller," said Sablon. Tesla Solar Trackers will work in series with the batteries and panels through pulsing so as to not harm your electronics. They will work with regular inverters and other equipment, so long as there is no voltage limiting circuitry involved, as there is in some equipment."
Sablon said the Company feels that, by offering the Tesla Solar Trackers, they can help their customers save time and money while shopping for their solar products, as well as increase the efficiency in their solar panel systems.
ELITE PHARMACEUTICALS INC. (OTCBB: ELTP)
"Up 67.66% on Tuesday"
Detailed Quote: www.otcpicks.com/quotes/ELTP.php
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Two of Elite's products, Lodrane 24® and Lodrane 24D®, are marketed by a partner, ECR Pharmaceuticals, for allergy treatment. Elite's lead pipeline products are novel sustained release oral formulations of oxycodone for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Both products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are in late-stage development. Elite, with partners, also has an ANDA filed with the FDA for a generic equivalent of a pain product and has a generic gastrointestinal drug product in clinical development. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
April 7 - Elite Pharmaceuticals Announces First Shipment of Generic Phentermine HCl Tablets
Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite") announced that the initial shipment of phentermine HCl 37.5 mg tablets, the generic version of Adipex-P® 37.5 mg tablets, was made, triggering a milestone payment under the License, Manufacturing and Supply Agreement with Precision Dose and its wholly owned subsidiary TAGI Pharma, Inc. TAGI Pharma will distribute the product as part of a multi-product distribution agreement.
Phentermine HCl is a member of the amphetamine and phenethylamine class. It is an appetite suppressant used to help reduce weight in obese patients when used short-term and combined with exercise, diet, and behavioral modification.
For the most recent twelve months ending December 2010, Adipex-P® and its generics had total U.S. sales of approximately $40 million according to IMS Health Data.
ABOUT TAGI PHARMA, INC.
TAGI Pharma was launched by Precision Dose in 2010 as a specialty pharmaceutical company focused on the Retail Market Segment. A key component of TAGI Pharma's strategy is the leveraging of its sales and distribution core competencies with the formation of strategic partnerships that have product development and manufacturing capabilities such as Elite. The phentermine HCl 37.5 mg product represents the first of these initiatives, and we expect an additional six product launches in the next six months. As the company sources products through development, acquisition and licensing opportunities, key areas of focus will be in the tablet, capsule and injectable dosage formats, with an emphasis on controlled substances, where there are additional barriers to entry.
KRAIG BIOCRAFT LABORATORIES INCORPORATED (OTCBB: KBLB)
"Up 32.14% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/KBLB.php
Kraig Biocraft Laboratories, Inc. focuses on the development of protein based fiber using recombinant DNA technology for commercial applications in the textile and specialty fiber industries. Its products are used in military and police departments; industrial applications, including critical cables and abrasion/impact resistant components; and consumer applications. These fibers are also employed in safety equipment, and high strength composite materials for the aero-space industry. The company was founded in 2006 and is based in Lansing, Michigan.
April 12 - Sigma-Aldrich and Kraig Biocraft Laboratories Successfully Negotiate License Agreement
* Sigma-Aldrich and Kraig to Work Together to Create the Next Generation Biomaterials
* Sigma-Aldrich Becomes Kraig Shareholder
Kraig Biocraft Laboratories, Inc. (OTC: KBLB) announced today that the Company has entered into a licensing agreement with biotechnology giant Sigma-Aldrich Inc. (Nasdaq: SIAL).
Kraig has successfully negotiated a license to use Sigma-Aldrich's powerful zinc finger technology to accelerate its scientific research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical fields.
Under the terms of the agreement announced today, Sigma will provide Kraig with its proprietary genetic engineering tools and expertise in zinc finger nuclease to enable Kraig to significantly accelerate its product development. In addition to providing the customized tools and technological know-how, Sigma has granted Kraig an option for a commercial license to use the technology in the textile and biomedical markets. Sigma has agreed that upon exercise of the option Kraig will have exclusive commercial rights to use Sigma ZFNs in conjunction with the insertion of more than two hundred proprietary spider silk sequences previously licensed by Kraig from a third party into the silkworm genome. Sigma-Aldrich will be creating customized zinc fingers for Kraig's use in its development of spider silk polymers and technical textiles.
"Sigma-Aldrich's proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting," said Kraig's CEO Kim Thompson. "We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials."
"ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics," said Dr. Joseph Bedell, Director of Sigma's Commercial Animal Technology Group. "Spider silk production is just the first example of a commercial animal application for this exciting technology."
"Kraig has the utmost confidence in the power of Sigma's zinc finger technology," said Mr. Thompson. "Sigma's agreeing to provide this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe that Sigma's zinc finger technology will reinforce Kraig's competitive advantage in the field of bio-materials and advanced silk polymers. Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich's revolutionary technology and know-how, coupled with Kraig's proprietary bio-materials technology and know-how, will create synergies that will benefit both companies.
Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service.